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Summary: The assay described in this article is based on microtitre plate technology; it employs an europium
label. The streptavidin-biotin system has been used and all components are commercially available.
The lower detection limit of the assay is below 0.003 mU/1; the standards are made up in newborn calf serum.
Correlation with a commercially available immunoluminometric assay (Berilux — Behringwerke) was excellent
(r = 0.92, n = 201 data pairs, range covered 0 —10mU/l). The regression line using a double logarithmic
transformation was: (log y) = 0.91 (log x) — 0.08.
The assay precision at the clinical limits of decision — i. e. between hyper- and euthyroidism (0.2 mU/1) and
eu- and hypothyroidism (4mU/l) — was acceptable. The median coefficient of variation was 1.93% in the
range 0.02—1 mU/1 and 2.11% in the range 1.0 — 3.5 mU/1, with both values being determined from precision
profiles using 214 and 188 data pairs respectively. Inter-assay coefficients of variation determined in over 30
consecutive assays were under 6% in the range 1.3 — 20 mU/1.
From 201 sera measured in both assays, 194 sera gave clinically identical values; 8 sera gave clinically
discrepant values.
The assay has a large dynamic range covering a concentration range of above 5 decades, with the count ratio
between the 100 mU/1 standard and the zero standard being in excess of 4150: 1. A high dose hook effect
was first seen in excess of 500 mU/1. The maximum signal was achieved around 150 mU/1, which registered
around 8 106 counts per second, a figure more than 8000 times higher than that in the zero standard.
Introduction . . , . ,· . . , .better, lower detection limit as compared with im-
The introduction of immunometric methods for thy- munoradiometric assays (4, 5). Some authors now go
rotropin (1, 2) led to an indirect standardisation of as far as prizing "third generation" thyrotropin assays
assays for this analyte, as well as to a shortening of (6), although the lower detection limit of a method
assay time and an improvement of the lower detection depends on the state of the art of analysis.
limit and analytical specificity. ™ , ,, . „ ,The lower detection of such assays is often more
The discrimination'between eu- and hyperthyroid pa- theoretical than practical, as the matrix of the zero
tients became possible with this "second generation" standard has been manipulated to give a low back-
of assays for thyrotropin (3). Further developments ground signal. More important, however, is the ability
in assay technique have led to non-radioisotopic im- of an assay for thyrotropin to discriminate correctly
munometric assays that have a comparable, if not between eu- and hyperthyroid patients in terms of
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defined reference ranges (6, 7), and it may very well
be that the methods giving the lowest thyrotropin
concentration are not necessarily those giving the best
clinical discrimination (6 — 8).
This brief communication describes the development
and clinical evaluation of an immunometric assay for
thyrotropin using a streptavidin-europium complex
as label. The assay appears to show no serum matrix
effects, which allows the standard curve to be set up
in assay buffer. Using human thyrotropin as standard
(calibrated against the WHO 2nd IRP 80/558), levels
of 0.001 mU/1 thyrotropin can be distinguished from




Ninety-six-well microtitre plates (Maxisorp) were obtained
from Nunc, Roskilde, Denmark.
Antibodies to thyrotropin were purchased from Boehringer-
Mannheim, Mannheim, Germany. These consisted of a mono-
clonal antibody, which was immobilised onto the microtitre
plate wells, and a polyclonal Fab fragment from sheep, which
was biotinylated by the authors.
Standards for thyrotropin used for calibration purposes were
obtained from the Behringwerke, Marburg a. d. L., Germany.
Human thyrotropin for internal standards was purchased from
Kabi (Kabi-Pharmacia, Erlangen, Germany).
Amidocaproylbiotin-N-hydroxysuccinimide was purchased
from Sigma, Deisenhofen, Germany, the europium labelling
reagent, from Pharmacia, Freiburg i. Br., Germany.
The Berilux TSH immunoluminometric assay (Behringwerke)
was used for comparison.
The time-resolved fluorimeter (Arcus 1232) was from Wallac,
Turku, Finland and the 250-sample semiautomated lumino-
meter (Berthold LB-952 16T) from EG&G Berthold, Wildbad,
Germany.
Other chemicals and buffer substances were obtained from
Sigma or Merck, Darmstadt, Germany.
All reagents were made up in the laboratory, including those
for the time-resolved fluorescence measurement. The assay buf-
fer and enhancement solution were made up as listed below:
Assay buffer
Tris 0.05 mol/1, NaCl 0.15 mol/1, bovine serum albumin 5 g/1,
bovine gamma globulins 0.5 g/1, diethylene triaminopentaace-
tate (DTPA) 80 mg/1, NaN3 0.15 mol/l, Tween 20 01 ml/1
adjusted to pH 7.75.
Wash solution
Tris 0.05 mol/1, NaCl 0.15 mol/1, EDTA 0.01 mol/1, NaN3 0 15
mol/1, Tween 20 0.1 ml/1, adjusted to pH 7.5.
Enhancement solution
Acetic acid 0.01 mol/1, tris-n-octyl phosphine oxide 38 mg/1,
potassium phthalate 166 mg/1, theonyltrifluoroacetone 222
mg/1, Triton X-100 2 ml/1.
Methods
The coating of the microtitre plates, the preparation of the
standards and the assay procedure are shown in table 1.
Tab. la. Components and assay scheme for the thyrotropin
time resolved imrmmofluorirnetric assay (TRIFMA)
— Coating of the microtitre plate
Each well was coated with 500 ng monoclonal antibody
MAK 8 in phosphate buffer, pH 8.7, using a coating volume
of 250 ui. The minimum coating time was 18 h at ambient
temperature. Saturation of free binding sites was performed
directly before assay using 50 mmol/1 carbonate buffer con-
taining 10 g/1 bovine serum albumin, pH 9.6, with a mini-
mum saturation time of 45 min and a volume of 350 μΐ/
well.
— Labelling of the liquid-phase antibody
Sheep anti-human thyrotropin (Fab fragment) was labelled
with amidocaproyl biotin N-hydroxysuccinimide ester at pH
9.4 for 18 h at ambient temperature. Separation of unreacted
biotin was performed on a 15 χ 1 cm column of Ultrogel
AcA-54 (IBF, Gif-sur-Yvette, F.) using 0.05 mol/1 Tris-HCl,
pH 7.5, as eluent.
— Preparation of standards
Human thyrotropin (Kabi-Pharmacia) was dissolved in a
minimal amount of 0.15 mol/1 NaCl and further diluted
with newborn calf serum to give a stock solution of around
3 U/l. Standards were made by diluting portions of stock
solution to give standards containing 100, 10, 1, 0.1, 0.01
and 0.002 mU/1 thyrotropin in newborn calf serum. These
standards were portioned and stored at under -30 °C until
use. Each portion was used for one assay, with any surplus
material being discarded.
— Assay scheme
— 100 μΐ standard, sample or control
— 100 μΐ biotinylated anti-thyrotropin
— incubate 120 rnin at ambient temperature on shaker
- wash with wash buffer (3 cycles on plate washer)
— 200 μΐ streptavidin-europium
- incubate 30 min as above and wash (5 cycles on plate
washer)
— 200 μΐ enhancement solution
- incubate as above and measure in ARCUS 1232 (1 s/
well)
The biotinylation of the antibodies was performed using the
active ester method with an N-hydroxysucciiiimide ester, as has
already been described in detail for both biotin (9) and lumi-
nogens (10).
The assay used for comparison (Berilux TSH) was set up
according to the manufacturer's instructions. The clinically
relevant ranges established in L beck for this kit were: hyper-
thyroid patients < 0.1 mU/1, euthyroid patients 0.2—3.4 mU/1
and hypothyroid patients > 5 mU/1. These are not identical
with those in the kit instructions, they have been established
over a 36-month period in which the kit was used routinely on
over 20000 samples.
Results
This assay demonstrates the .wide measuring range
obtainable through low background and high specific
signal (dynamic signal range). Table 2 shows a com-
pound standard curve to demonstrate this point. The
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Tab. 2. Standard curve and precision data for thyrotropin








































































maximal signal is reached at a concentration around
150 mU/1 and reaches almost 8 χ ΙΟ6 counts per
second. A high dose hook effect is first seen in excess
of 500 mU/1, i. e. at concentrations which do not occur
physiologically.
Table 2 also shows the intra- and inter-assay precision,
as well as a precision profile, with the latter repre-
senting the precision obtained with patient samples.
The sample P2 is a single patient serum, samples Kl,
K3—K8 commercial control sera. The imprecision of
P2 is higher than that of Kl, reflecting a state of
affairs often occurring, i. e. that the relative standard
deviation (s%) is higher in native sera than in proc-
essed control sera.
The precision control data reflect the excellent preci-
sion at the "levels of clinical decision" between hyper-
and euthyroid patients around 0.2 mU/1 and between
eu- and hypothyroid patients around 4 mU/1.
The median concentrations of the 201 sera measured
in a correlation study were 1.00 mU/1 for the com-
mercial ILMA and 0.80 mU/1 for the TRIFMA. These
data are shown in figure 1. Both assays classified the
patients with confirmed hyperthyroidism and euthy-
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Fig. 1. Comparison of the commercial immunoluminometric
assay (Berilux) (x) and the time-resolved immunofluor-
imetric assay (y) as determined on 201 patient sera
covering the range 0—10 mU/1. A double logarithmic
scale was used to emphasize the values at lower concen-
trations. Values below the detection limit of each assay
were given as 0.001 mU/1. The regression line is (log y)
= 0.91 (logx) -0.08, the coefficient of correlation r
was 0.92. The hyperthyroid (heavy shading) and euthy-
roid (light shading) ranges are shown. Discrepant results
lie in the areas without shading.
TRIFMA gave results as borderline, the ILMA as
euthyroid; in two cases, the TRIFMA classified pa-
tients as borderline, the ILMA as hyperthyroid; and
in one case, the TRIFMA classified a patient as
borderline euthyroid, the ILMA as borderline hyper-
thyroid.
Discussion
The continual improvement of immunoassays for pro-
teohormones has led to a more reliable diagnosis in
the clinic. The differences between radioimmunoas-
says and immunometric assays for thyrotropin has
been documented elsewhere, as far as performance is
concerned. The in-vitro differentiation between hyper-
and euthyroidism first became possible with the in-
troduction of the immunoradiometric assays for thy-
rotropin. The reduction of assay times from several
days to a couple of hours made emergency confir-
mation of overt hyperthyroidism or thyrotoxic crisis
possible, with the results being back on the ward
within two or three hours (1 —3, 7).
The assay reproducibility at low analyte levels was
vastly improved by the reduction of the detection
limit and by the robust assay design.
The introduction of non-radioisotopic labelling has
not only removed the hazards of radionuclides, but
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has also led to a further improvement in assay lower
detection limits and to the shelf-life of components,
especially the tracer. In addition, the circle of immu-
noassay kit users has been increased, as no licensing
of laboratories for radioisotopes is needed for the
non-radioisotope labelled kits.
It is important not to forget the problems of meas-
uring low analyte concentrations where "matrix ef-
fects" play a significant role (11). At worst, the effects
may give rise to spuriously elevated results due to
non-specific binding of tracer in two-site immuno-
metric assays (7). The causes are many and include
immunoglobulins (12, 13), anti-mouse IgG (14) and
rheumatoid factor (15), to name but three. Vaidya &
Beany (16) have investigated the sources of interfer-
ence in assays using creatine kinase-MB as a model
system.
From the above studies and observations it is clear
why the aim must be to develop assays that are
insensitive to such effects of components in the matrix
(11, 16).
The assay described here appears to fulfil the criterion,
at least under the conditions tested, of being matrix-
independent. That the assay results are identical, in-
dependent of whether the standards are dissolved in
assay buffer, foetal calf serum or human serum from
a thyrotoxic patient supports the claims of the assays
as being relatively free from serum matrix effects. The
addition of "blocking antibodies" (MAK 33 — anti
CK-MM Boehringer-Mannheim) is designed to act
against so-called human-anti-rjiouse-antibodies some-
times present in patients treated for cancer with
tagged monoclonal antibodies (12). As the antibody
used to coat the solid phase was of murine origin, it
was not surprising to find that the non-specific bind-
ing of tracer to the solid-phase was reduced, and that
no spurious results were obtained from the patient
sera, although no screening for anti-mouse antibodies
had been made, in contrast to other studies (14, 16).
The excellent correlation with the commercial kit in
the lower concentration range emphasizes the quality
of the assay developed here. The values that lie below
those of the commercial kit document the extremely
low background of the europium fluorescence in the
assay developed.
This short communication shows that it is still pos-
sible to develop immunoassays in hospital laborato-
ries with comparable performance to those from com-
mercial kits. This may not be of primary interest in
the industrialised countries, but may play a major role
in developing countries. The method developed here
was made in conjunction with the International Coun-
cil for Control of Iodine Deficiency Disorders
(ICCIDD).
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